Aragon Pharmaceuticals aragonpharm.com


Public list: Pharma Startups (6570) Cancer Therapeutics (1180)

Aragon Pharmaceuticals is a small-molecule drug discovery company focused on developing medicines for the treatment of hormonally-driven cancers. These cancers eventually become resistant to existing 1st generation antihormonal therapies, and follow-up treatments are largely ineffective or toxic. The company's lead compound, ARN-509, is an antiandrogen undergoing a Phase I/II clinical trial in patients with progressive, advanced castration-resistant prostate cancer. In addition to ARN-509, Arago...Show all

Aragon Pharmaceuticals is a small-molecule drug discovery company focused on developing medicines for the treatment of hormonally-driven cancers. These cancers eventually become resistant to existing 1st generation antihormonal therapies, and follow-...Show all

Company (Acquired)

Phone: 858-334-4830

Fax: 858-334-4848

12780 El Camino Real
Suite 301
San Diego, 92130
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Aragon Pharmaceuticals $122M Aug 19, 2013
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Aragon Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 5 investors

Competitors

Company Status Description Investors

Syndax Pharmaceuticals

Waltham, Massachusetts, United States
IPO / Went publicSyndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma and triple negative breast cancer. Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body's immune response to tumors. Entinostat is being evaluated in a Ph...Show allLogin to see details

Celera Genomics

Rockville, Maryland, United States
AcquiredCelera Genomics is one of three business segments of Applera Corporation. Celera Genomic's mission is to discover and develop meaningful new therapies that improve human health. We are applying our diverse genomics, bioinformatics, proteomics, medicinal chemistry and biology technology platforms to identify and validate drug targets, and to discover novel therapeutics. Celera Genomics currently has a portfolio of programs based primarily on protease inhibitors for three major therapeutic areas: ...Show allLogin to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer Sep 23, 2013 Feb 06, 2018 Patent
Methods and compositions for determining resistance to androgen receptor therapy Jul 26, 2013 Apr 11, 2017 Patent
Androgen receptor modulators and uses thereof Mar 12, 2015 Nov 01, 2016 Patent
Crystalline forms of an androgen receptor modulator Jun 04, 2013 Nov 01, 2016 Patent
Androgen receptor modulators and uses thereof Feb 16, 2011 Aug 18, 2015 Patent
See all 15 patents